|
US2017296637A1
|
|
Chagas antigens and antibodies and compositions, methods and uses thereof
|
|
EP3077417A1
|
|
Hiv antigens and antibodies and compositions, methods and uses thereof
|
|
AU2013201008A1
|
|
Peptide sequences and compositions
|
|
AU2013200258A1
|
|
Peptide sequences and compositions
|
|
GB201108234D0
|
|
Pharmaceutical agent
|
|
AU2010264764A1
|
|
Pharmaceutical agent
|
|
GB0920790D0
|
|
Pharmaceutical agent
|
|
GB0913956D0
|
|
Pharmaceutical agent
|
|
GB0910754D0
|
|
Pharmaceutical agent
|
|
GB0905558D0
|
|
Pharmaceutical agent
|
|
GB0905555D0
|
|
Pharmaceutical agent
|
|
GB0905557D0
|
|
Pharmaceutical agent
|
|
NZ602090A
|
|
Peptide sequences and compositions
|
|
GB0718045D0
|
|
Pharmaceutical compound
|
|
GB0717864D0
|
|
Peptide sequences and compositions
|
|
CN104558126A
|
|
Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof
|
|
UA100496C2
|
|
Peptide sequence which is immunogenic in a vertebrate and a composition
|
|
GB0614260D0
|
|
Peptide sequences and compositions
|
|
GB0613977D0
|
|
Peptide sequences and compositions
|
|
GB0604920D0
|
|
Peptide sequences and compositions
|
